Heron Therapeutics Inc vs Vipshop Holdings Ltd - ADR — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Vipshop Holdings Ltd - ADR trades at $12.71 (market cap $6.07B). The key difference: Vipshop Holdings Ltd - ADR is far larger — about 82× Heron Therapeutics Inc's market cap, and Vipshop Holdings Ltd - ADR pays a 4.86% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vipshop Holdings Ltd - ADR for 49 Days on average.
| HRTX | VIPS | |
|---|---|---|
Market Cap | $74.04M | $6.07B |
Volume | 3,668,095 | 3,134,219 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $20.29 |
52-Week Low | $0.27 | $12.09 |
Typical Hold Time | 35 Days | 49 Days |
Enterprise Value | $180.78M | $2.90B |
Dividend Yield | — | 4.86% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Vipshop (VIPS) trades at $12.72, down 0.24% on the day, with a bullish overall technical signal. The stock appears undervalued with a P/E of 4.12 and P/S of 0.41, supported by strong profitability metrics including a 9.82% net income margin and 24.44% ROE. Recent Q2 2026 earnings missed expectations, with revenue of $105.92 billion in 2025 showing a slight decline, but net income remains robust at $7.24 billion. Analyst consensus is bullish with a $16.17 price target.
The outlook for VIPS is mixed; attractive valuation and strong cash flow generation offer upside potential, but recent earnings misses and a challenging consumer environment pose near-term risks. Investor sentiment is cautiously optimistic, with 53.57% of analysts rating it a buy, though growth stagnation remains a key concern.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →